Apokyn Bertek Pharmaceuticals - Treatment for Parkinson’s Disease

Apokyn (apomorphine hydrochloride injection) is the first and only therapy in the United States for the acute, intermittent treatment of hypomobility, “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) associated with advanced Parkinson’s disease.

Posted: April 2004

Apokyn (apomorphine) FDA Approval History

More News Resources

Drug Status

Availability Rx Prescription only

Pregnancy Category C Risk cannot be ruled out

CSA Schedule N Not a controlled drug

Approval History Calendar Drug history at FDA

Recently Approved

Trelegy Ellipta Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) is an inhaled corticosteroid,...
Adzenys ER Adzenys ER (amphetamine) is an extended-release liquid suspension formulation of the central...
Solosec Solosec (secnidazole) is a nitroimidazole antimicrobial for use as a single-dose oral therapy in...
Aliqopa Aliqopa (copanlisib) is a phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the...

More

Available RSS Feeds

Select any link below to view the RSS feed.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated Sep 1st, 2017), Cerner Multum™ (updated Sep 4th, 2017), Wolters Kluwer™ (updated Sep 6th, 2017) and others. To view content sources and attributions, please refer to our editorial policy.

Apokyn Bertek Pharmaceuticals - Treatment for Parkinson’s Disease

More News Resources

Drug Status

Support

About

Terms & Privacy

Apokyn Bertek Pharmaceuticals - Treatment for Parkinson’s Disease

More News Resources

Drug Status

Drugs.com Mobile Apps

Support

About

Terms & Privacy

Hide